Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Neumora Therapeutics, Inc.(NMRA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NMRA
11/11/2026: NMRA (1-star) is currently NOT-A-BUY. Pass it for now.
Neumora Therapeutics is a clinical-stage biotechnology company that aims to innovate in neuroscience by utilizing a precision medicine platform. Its primary investment story centers on the potential of its pipeline, including Navacaprant for depression, to address significant unmet medical needs. While the company benefits from strategic partnerships and a robust R&D approach, it faces substantial risks, including the high failure rate of clinical trials and the need for future capital. The stock is best suited for growth-oriented investors who can tolerate high volatility and extended timelines. Investors should closely monitor clinical trial milestones and regulatory developments that are essential for long-term viability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to binary clinical trial outcomes rather than established revenue growth. |
| Momentum investor | Mixed fit | Momentum is highly sensitive to news flow regarding clinical trial data and regulatory updates. |
| Value investor | Weak fit | Traditional value metrics like P/E are not applicable as the company is not profitable. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on reinvestment. |
| Low-risk investor | Weak fit | High volatility and clinical/regulatory risks make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp price swings based on trial results. |
| Valuation risk | Medium / high | Valuations are speculative and highly dependent on long-term project success. |
| Competition risk (Neuroscience drug development) | High | Numerous well-capitalized firms are pursuing similar patient populations. |
| Business quality | Medium | The company has strong scientific backing but lacks a track record of commercialization. |
| Dividend income | Low / none | The company provides no income to shareholders. |
| Execution risk | High | Successfully managing large-scale clinical trials and navigating the FDA approval process is extremely difficult. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -25.31% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/11/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Sector & Industry Intelligence
Sector snapshot as of 2026-11-10
Sector
Healthcare
- Signal
- Constructive
- Sentiment
- Strong Bullish
- Market state
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 60.0%
- Active BUY / eligible
- 69 / 115
- 22-session BUY-count change
- +29
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.5%
- Active BUY / eligible
- 20 / 46
- 22-session BUY-count change
- +12
The sector signal does not change this stock’s BUY, SELL, or PASS advisory.
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 87.67M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 2.0M shares | Beta 3.14 | 52 Weeks Range 0.32 - 3.65 | Updated Date 11/10/2026 |
52 Weeks Range 0.32 - 3.65 | Updated Date 11/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.23 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research and Development / Licensing | Potential future milestone payments, royalties, and commercial revenue from licensed or owned therapies. | The company currently makes no money; it is betting on the success of its drug pipeline to generate future income. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27.72M | Price to Sales(TTM) - |
Enterprise Value 27.72M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.65 | Shares Outstanding 187.90M | Shares Floating 116.41M |
Shares Outstanding 187.90M | Shares Floating 116.41M | ||
Percent Insiders 23.08 | Percent Institutions 59.9 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.